Trouble reading this email? View it in your browser
European Federation of Pharmaceutical Industries and Associations EFPIA Newsletter 05 November 2026
      Blogs
 
  04 November 2026 Obesity science has changed. Health policies must change too (Guest blog)

In the past, obesity was erroneously viewed primarily through the lens of personal responsibility. The flawed prevailing...

Read more →
 
 
 
      Hey, it's #MedSafetyWeek

We’re proud to join forces with medicines regulatory authorities and partners from 130 countries worldwide to encourage the reporting of suspected side effects from medicines.

Every report of suspected side effects matters: medicines are continuously monitored to ensure their safety, and reports form an essential part of global pharmacovigilance systems. Your reports help regulatory agencies and pharmaceutical companies learn more about the safety of medicines, helping to improve patient safety worldwide.

Learn more here.

 
 
      What is the impact of overweight and obesity in Italy?

A recent report by the Office of Health Economics, commissioned by EFPIA, shows that elevated BMI is associated with 278,000 deaths and almost 8 million years of healthy life lost annually across eight European countries. The economic costs are equally significant, accounting for 0.6% to 1.4% of national GDP.

Elevated BMI costs Italy an estimated €20.3 billion annually (€345 per capita), split between €12.9 billion in direct costs (63%) and €7.5 billion in indirect costs (37%). Overall, expenditure related to elevated BMI amounts to roughly 0.9% of GDP, approaching the amount of government spending on defence.

Find out more in the report and the infographic.

 
 
 
      Events
 
 
11 NOV 2026
  Health Means Wealth conference Prague, Czech Republic

The Health Means Wealth conference will explore how investing in health and innovation can strengthen health system...

Learn more →
 
 
 
17 NOV 2026
  Europe's Life Sciences Competitiveness Agenda - Innovation, investment and global... Hybrid

Organised by Rapporteur, this event will explore how Europe can strengthen its life sciences competitiveness and improve...

Learn more →
 
 
 
15 FEB 2027
  Save the Date: EURORDIS Black Pearl Awards 2027 Brussels

The EURORDIS Black Pearl Awards are returning to Brussels, bringing together the rare disease community to celebrate...

Learn more →
 
 
      What we are reading
Pharma’s push for higher drug prices gains support in Europe 04 November 2026  (Politico) Read more →
The pharmaceutical industry and its ecosystem: A challenge for Europe 02 November 2026  (Les Annales des mines) Read more →
From medicines shortages to medicines security: Building a more resilient European healthcare... 14 October 2026  (Healthcare Chain Institute) Read more →
Why patient access must keep pace for innovative medicines 12 October 2026  (Drug Discovery World) Read more →
    About the EFPIA newsletter

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 36 national associations and 39 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.

 
Tel: +32 (0)2 626 25 55
Communications@efpia.eu
▶ in
 
EFPIA 2026 All rights reserved  ·  Disclaimer  ·  Unsubscribe